Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …

Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …

These updated EBMT guidelines review the clinical evidence, registry activity and
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

The potent pleiotropic lipid mediator sphingosine-1-phosphate (S1P) participates in
numerous cellular processes, including angiogenesis and cell survival, proliferation, and …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …

Pediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and
neurodegenerative disease that has a significant impact on long-term physical and cognitive …